Targeting Oncogenic Mutant p53 for Cancer Therapy
Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional p53 protein in tumors. These mutants frequently hav...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
Frontiers Media S.A.
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685147/ |